MedicaidCoverageMedium impact
KMAP BULLETIN: Preferred Drug List Update – May 2026
Kansas Medicaid (KanCare)·KS · Pharmacy, Endocrinology, Pain Management +2 more·Pharmacy
Effective date
May 1, 2026
We identified it
Jun 21, 2026
Summary
KMAP updated their Preferred Drug List effective May 1, 2026, moving 11 medications to non-preferred status (including Arynta, Nucynta, and others), adding 2 medications to preferred status (Wegovy and HD Tryngolza), and removing 3 cystic fibrosis medications from the PDL entirely. This will affect prior authorization requirements and patient cost-sharing for these medications.
Action Required
By May 1, 2026: Billing team must update prior authorization workflows for newly non-preferred medications including Arynta, Atmeksi, Aukelso, Bosaysa, Metoprolol tartrate 12.5mg, Nucynta, Nucynta ER, Ontralfy, Redemplo, Sdamlo, sodium sulfacetamide-sulfur, and Zybic. Update patient counseling materials to reflect that Wegovy and HD Tryngolza are now preferred options. Note that Kalydeco, Orkambi, and Symdeko are removed from PDL entirely. Monitor KanCare MCO implementation dates as they may vary from the state effective date.